Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months

Figure 1

Systemic manifestations over time in patients with sJIA treated with tocilizumab (𝑛=75). Here and after: ^∗𝑃<0.01, ^∗∗𝑃<0.001.